INAB (IN8bio) Piotroski F-Score: 4 (As of Jun. 28, 2026) — 33% Above Median


INAB IN8bio Inc INAB
24 GF Score
Price $1.36
View Full Analysis

What is IN8bio Piotroski F-Score?

IN8bio INAB -0.45% 24 Piotroski F-Score is 4 as of Jun. 28, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates INAB with a GF Score™ of 24/100. Among 1,340 Biotechnology companies, IN8bio ranks better than 74.18% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

IN8bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for IN8bio's Piotroski F-Score or its related term are showing as below:

INAB' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 4

During the past 8 years, the highest Piotroski F-Score of IN8bio was 4. The lowest was 1. And the median was 3.

IN8bio  (NAS:INAB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


IN8bio Piotroski F-Score Related Terms


IN8bio Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for IN8bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IN8bio Piotroski F-Score Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 4.00 2.00 3.00 2.00 3.00

IN8bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 3.00 3.00 4.00

INAB vs ZIVO, LPCN, CTXR: Piotroski F-Score Comparison

For the Biotechnology subindustry, IN8bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IN8bio Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where IN8bio's Piotroski F-Score falls into.


INAB
24GF Score
IN8bio Inc INAB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -5.094 + -3.854 + -4.942 + -5.09 = $-18.98 Mil.
Cash Flow from Operations was -3.927 + -3.524 + -2.139 + -4.947 = $-14.54 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(19.869 + 19.371 + 16.768 + 32.282 + 26.265) / 5 = $22.911 Mil.
Total Assets at the begining of this year (Mar25) was $19.87 Mil.
Long-Term Debt & Capital Lease Obligation was $1.33 Mil.
Total Current Assets was $22.66 Mil.
Total Current Liabilities was $2.16 Mil.
Net Income was -8.629 + -7.086 + -6.16 + -5.55 = $-27.43 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(25.549 + 22.496 + 15.966 + 20.944 + 19.869) / 5 = $20.9648 Mil.
Total Assets at the begining of last year (Mar24) was $25.55 Mil.
Long-Term Debt & Capital Lease Obligation was $3.04 Mil.
Total Current Assets was $12.73 Mil.
Total Current Liabilities was $2.96 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

IN8bio's current Net Income (TTM) was -18.98. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

IN8bio's current Cash Flow from Operations (TTM) was -14.54. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-18.98/19.869
=-0.95525693

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-27.425/25.549
=-1.07342753

IN8bio's return on assets of this year was -0.95525693. IN8bio's return on assets of last year was -1.07342753. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

IN8bio's current Net Income (TTM) was -18.98. IN8bio's current Cash Flow from Operations (TTM) was -14.54. ==> -14.54 > -18.98 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1.326/22.911
=0.05787613

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=3.035/20.9648
=0.14476647

IN8bio's gearing of this year was 0.05787613. IN8bio's gearing of last year was 0.14476647. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=22.662/2.158
=10.50139018

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=12.725/2.957
=4.30334799

IN8bio's current ratio of this year was 10.50139018. IN8bio's current ratio of last year was 4.30334799. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

IN8bio's number of shares in issue this year was 19.467. IN8bio's number of shares in issue last year was 2.575. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

IN8bio's gross margin of this year was . IN8bio's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0/19.869
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/25.549
=0

IN8bio's asset turnover of this year was 0. IN8bio's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

IN8bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
IN8bio (INAB) has a Piotroski F-Score of 4 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on IN8bio and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, IN8bio's Piotroski F-Score has ranged from 1.00 to 4.00. According to the industry distribution chart, IN8bio ranks #346 out of 1340 companies in the Biotechnology industry, placing it in the top 25.8%.
Is IN8bio's Piotroski F-Score too high?
IN8bio's current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. The Biotechnology industry median Piotroski F-Score is 3.00. IN8bio's value of 4 is 33.3% above this industry median. Based on the distribution chart, IN8bio ranks #346 out of 1340 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IN8bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's Piotroski F-Score compare to ZIVO and LPCN?
According to the Biotechnology industry distribution chart, IN8bio ranks #346 out of 1340 companies for Piotroski F-Score. This puts IN8bio in the upper half of its industry. The industry median Piotroski F-Score is 3.00. IN8bio's value of 4 is 33.3% above this benchmark. Historically, IN8bio's own Piotroski F-Score has ranged from 1.00 to 4.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, IN8bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,340 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IN8bio's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on IN8bio and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IN8bio's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 33.3% above the Biotechnology industry median of 3.00. IN8bio's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For IN8bio (INAB), the current Piotroski F-Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IN8bio Business Description

Address 350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score

Get the complete analysis for INAB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price